WWW.IJRPR.COM

**International Journal of Research Publication and Reviews**

Journal homepage: www.ijrpr.com ISSN 2582-7421

# Review on Liquid Biopsy

***[1]Mr. Harshad Balaji Kamble, [2]Mr. Pawar Rohit K.***

[1]Student, LNBCIOP, Raigaon, Satara
[2]Asst. Prof., LNBCIOP, Raigaon, Satara

**ABSTRACT**

liquid biopsy may be used to help find cancer at an early stage.a laboratory test done on a sample of blood, urine, or other body fluid to look for cancer cells from a tumor or small pieces of DNA, RNA, or other molecules released by tumor cells into a person's body fluids.

Liquid biops gives us real time information It inform us what happen at the molecule level from our tumor It information from all the lessions because potentially at the tumor form that one patient shed DNA into blood strain A liquid biopsy do all that very fast potentious cheaper and non aggresive for the patientLiquid biopsy allows multiple samples to be taken over time, which may help doctors understand what kind of genetic or molecular changes are taking place in a tumor

**Keywords:** liquid biopdy, ctDNA, cfDNA, CTCs, Tumour,

## 1. Introduction

Liquid biopsy' was introduced as a new demonstrative idea in 2010for the analysis of circulating tumor cells (CTCs) hereditary of tumor patients and has happened immediately extended to the reasoning of circulating tumor-derived determinants, in particular, cell-free tumor DNA (ctDNA), in addition to extracellular vesicles (EVs), cell-free microRNAs (cfmiRNAs), mRNA, long noncoding RNA, narrow RNA, circulating cell-free proteins, and tumor-educated platelets (TEPs). Liquid biopsy is a minimally invasive process occasionally based on inspecting of ancestry, but also of cerebrospinal fluid, urine, spit, ascites, and theoretically some other body fluid..1 Sciences for ctDNA/cfDNA discovery:

-Te following techniques are with those that have acted deployed to check ctDNA/cfDNA: droplet digital polymerase chain reaction (ddPCR), pendants, emulsion, amplifcation, and magnetics (BEAMing), tagged-amplicon deep sequencing (TAm-Seq), cancer personalized profling by deep sequencing (CAPP-Seq), whole genome bisulfte sequencing (WGBS-Seq), whole exome sequencing (WES), and whole genome sequencing (WGS)






## 2. Advantages and disadvantages of liquid biopsy:-

***2.1Advantages***

Liquid biopsy have so many benefits ,, they are non invansive and non expensive Liquid biopsy have potential to better catch hetrogenecity tumour across location comnopare to tissue biopsy Liquid biopsy can be obtained successively to observe changes among therapy…2.2 disadvantages Tere are also various restrictions of liquid biopsies . ctDNA/cfDNA maybe drop in only small amounts and not all cases will have detectable levels, especially those with poor tumor burden. Because of the small amount of material shed in the circulation, sequencing can be difcult and expensive. Uniformity across research laboratories and merchants is wanted to ensure reproducibility. Not all detectable cfDNA alterations are tumor-connected; indeed, cfDNA can be confounded by the mutations derived clonal hematopoiesis of indeterminate potential (CHIP), specifically in earlier cases Furthermore, not all ctDNA/cfDNA is equally shed from the basic tumor and metastases, so it is unclear if the alterations discovered correctly show tumor variety. Dropping of ctDNA maybe suppressed by therapy and can be limited at definite disease sites 2

## 3. Elements of Liquid Biopsy

The traditional biopsy includes cells and tissue from the lesion.Howwere the liquid biopsy includes circulating tumour cell CTCs. Cell free DNA (cfDNA) and exosomes .. all along the initia period of oncogenesis And metastatis the basic tumour shed all cell cfDNA or exosomes That carry vital facts of the basic tumour….

***3.1 CTCs***

The origins of the CTCs are twain from the basic (mainly) andmetastatic sites. The certain clone of the primary tumour gets near the distribution and scatters to the distant organs. These CTCs can be sincerely released from the main tumour or they can be justthe apoptotic cell. The overall half-life of CTCs is hardly 1-2 hours.After, the CTCs are away from the distribution either by clearance in the liver or by combination in the metastatic sites. The circulating tumour cells maybe recognized by the appearance of cytoker-atin and epithelial cell adhesion molecule (EpCAM) on their cell sur-face as well the lack of CD 45.

***3.2 cfDNA:-***

The origins of cfDNA of tumour cells in the blood circulation contain: (a) the tumour proper; (b) CTCs; (c) metastatic tumour.cfDNA is came from the apoptotic cell, noxious tumour cells, alive release from the practicable tumour cells and too from the demolition of CTCs. cfDNA at first comes into distribution as a nucleosomal complex that includes two together Heredity and histones and subsequently Chromosome is freed from the nucleosome complex These cfDNAs are double-stranded and have much lower microscopic weight than that of genomic DNA via rupture in the distribution. The half-life of cfDNA is 16-30 minutes and it is likelycleared principally by liver and kidney.

***3.3 extracellular vesicles :-***

Extracellular vesicles are another component of liquid biopsy that are released two together from the normal as well tumour cells and are about the two together blood and in the differing body fluids. They are membrane bound vesicles and consist of exosomes, microvesicles and apoptotic bodies. The exosomes are nano-sized vesicles inasmuch as microvesiclesare micron-sized vesicles and larger in size. The exosomes include protein, lipids, mRNA, Deoxyribonucleic acid, mi-RNA and sRNA and carry many tumour exact valuable information.They are produced inside the endoplasmic networks and

are announced from the red body fluid membrane of the tumour cells. Afterward, the exosomes are detached from the distribution with the help of phagocytosis of the receiver cells. The half-life of the exosomes is short and 90% are cleared from the circulation inside 30 minutes. 3

## 4) Liquid biopsy used in disease

1) Breast Cancer

2) Colorectal Cancer

3) Liver Cirrhosis

4) Lung Cancer

5) Pancreating Cancer

Pdf name;- liquid examination for malignancy

### *4.1 Breast cancer*

2. Breast Cancer Screening Utilizing Liquid BiopsyIn the context of a BC diagnosis, mammography is the entrenched golden standardfor screening in clinical practice Still. in current decades, several studies have proposed to expand non-obtrusive methods for the early find of breast cancer Biomarkers based on cfDNA, ctDNA, CTCs, miRNA, lncRNAs, platelets, mRNA, protein, and volatile organic compounds (VOCs) have been earlier described and possibly derived from the blood (plasma/serum), urine, and slaver..Few studies have established cfDNA as an early detection biomarker in BC based onanalyses of Gene damage and DNA methylation changes. got a Herediyintegrity index using plasma where patients beside rooted malignancy had significantlygreater Chromosome damage than those with benign breast lesions and healthful controls, and skilledwas a correlation among TNM staging.

In another study, were the first to evaluateEGFR and PPM1E promoter methylation status, known to play an important duty in cancerevolution and tumorigenesis, in plasma applying next-era bisulfite sequencing. Inline with what is known about promoter hypermethylation and cancer, they noticed thatpatients accompanying BC had significantly higher methylation levels than healthful controls.Circulating tumor DNA maybe used as a potential biomarker in LB samples to iden-tify particular mutations in breast cancer 4.

### *4.2 Colorectal cancer*

colorectal cancer CRC is third most prevailing cancer worldwide…. Although the high death rates observed in the advanced stages, CRC is usuallya preventable malignity through shield forms.. The vast majority of CRC cancers progress gradually, as a result of multiple histological, morphological and genetic alterations. Before the basic Cancer produces notable symptoms (pain, constipation, bowel obstacle and bleeding), the stages of CRC evolution maybe noticed along thehelp of screening tests Screening patterns require either direct visualization of thelesion by endoscopic judgment (colonoscopy, sigmoidoscopy, or computed tomographycolonography), or discovery of weird DNA and/or hemoglobin as indicators of supernaturalblood in the seat through stool-based tests (fecal occult blood test, fecal immunochemicaltest, or multitarget stool DNA testing5

### *4.3 Liver cirrhosis*

Chronic liver diseases (CLD) is a major universal public well-being issue estimated to influence 844 million people and cause 2 million dying per year . In contrast to many chronic illnesses, a big proportion of CLD maybe prevented, medicated and/or even cured if diagnosed early that form methods for prompt diagnosis precariously important With the CLD, liver cancer is the second leading cause of cancer-related end of life everywhere Among all basic liver cancers, hepatocellular carcinoma (HCC) is the most common, accompanying nearly 90% of cases 6 .

Traditional liver biopsy remnants win standard to diagnose CLD and assess the pattern and asperity of affliction in individual victims, because now available non-invasive tests, including depict and serological methods, lack the sensitivity and specificity to recognize early stages of fibrosis and are not beneficial in the intolerance of inflammation from hepatocellular injury.

While tissue biopsy is an main and useful diagnostic tool it is two together invasive and challenging of significant sample preparation and judgment by a pathologist, variations in both sampling and interpretation, plus the restraint of the analysis to the disease stage when acted do not supply the level of detailed molecular information-in theory possible about an individual patient's disease.7

### *4.4 Lung cancer:*

clinical applications Lung cancer (LC) is ultimate ordinary cancer in the world with the topmost mortality rate compared to different Cancer entities89 (1.8 milliondeaths in 2018, WHO World Cancer Report).Nonsmall cell lung cancer (NSCLC) accounts for nearly 85% of all diagnosed LCs,where the most repeatedly diagnosed histological subtypes are adenocarcinoma (ADC, 40%-50% of diagnosis) and squamous cell tumor(SCC, 20-30% of diagnosis).90 Small cell bronchi cancer (SCLC) gives reason for approximately 15% of all diagnosed LCs, where the victims are often heavy smokers and Cancer cells express neuroendocrine indicators.

### *4.5 Pancreatic Cancer*

Image of the pancreas plays a key function in the description of pancreatic central lesions and in the staging, surgical planning, and treatment monitoring of pancreatic tumor.Diagnosis of pancreatic tumor depends clinical symptoms understood by imaging along US, CT, MRI, PET, and endoscopic US.CT is the imaging approach of choice for evaluation of pancreatic cancer, even though US, endoscopic US, contrast material enhanced US, and MRI accompanying MR cholangiopancreatography supply complementary information Endoscopic US is the most impressionable approach for the early detection of lesions; it allows almost easy access to the pancreas for tissue diagnosis by using fine-needle aspiration and contributes to tumor staging. MRI with MR cholangiopancreatography and PET scanning can too have a successful role as a secondary imaging approach under special circumstances when CT and endoscopic US are not diagnostic .The potential function of ctDNA in several facets of pancreatic cancer contains screening, prognosis, treatment selection, and detection of recurrence. Some small studies have showed that ctDNA can be discovered in a majority of cases with metastatic pancreatic cancer

## Conclusion :

CONCLUSION. The role of liquid biopsy of circulating tumor markers in the early diagnosis of cancer will continue to evolve. Improving technology and decreasing costs could allow liquid biopsy to serve as a highly sensitive and specific tool for aiding in earlier diagnosis of cancer in the near future.

Liquid biopsies consist of isolating tumor-derived entities like circulating tumor cells, circulating tumor DNA, tumor extracellular vesicles, etc., present in the body fluids of patients with cancer, followed by an analysis of genomic and proteomic data contained within them.

A liquid biopsy is a blood test that detects signs of cancerous tumors, including tumor cells and cancer cell DNA. Current U.S. FDA-approved tests can detect some types of advanced cancers, predict prognosis and help healthcare providers make treatment decisions.

**Reference:**

1) https://febs.onlinelibrary.wiley.com/doi/full/10.1002/18780261.12997#:~:text='Liquid%20biopsy'%20was%20introduced%20as,as%20extracellular%20vesicles%20(EVs)%2C

2) Mina nikanjam liquid biopsy current technology and clinical applications et al. journal of haematology and oncology (2022) 15;131

3) Ghosh RK, Pandey T, Dey P. Liquid biopsy: A new avenue in pathology. Cytopathology. 2019;30:138–143

4) Freitas, A.J.A.d.; Causin,R.L.; Varuzza, M.B.; Calfa, S.; Hidalgo Filho, C.M.T.; Komoto, T.T.; Souza,C.d.P.; Marques, M.M.C. LiquidBiopsy as a Tool for the Diagnosis, Treatment, and Monitoring of BreastCancer. Int. J. Mol. Sci. 2022, 23, 9952. https://doi.org/10.3390/ijms23179952

5) Galos, D.; Gorzo, A.;Balacescu, O.; Sur,D. Clinical Applications of Liquid Biopsy in Colorectal Cancer Screening: Current Challenges and Future Perspectives.Cells 2022, 11, 3493. https://doi.org/10.3390/cells11213493j

6) Marcellin P, Kutala BK. Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening. Liver International 2018;38, 2–6. https://doi.org/10.1111/liv.13682

7) Barrera-Salda ˜na HA, Fern´andez-Garza LE, Barrera-Barrera SA,Liquid biopsy in chronic liver disease, Annals of Hepatology (2020), https://doi.org/10.1016/j.aohep.2020.03.008

8) Jacob J. Underwood, DO1 • Rehan S. Quadri, MD2 • Sanjeeva P. Kalva, MD • Hriday Shah, MD3 • Aravind R. Sanjeevaiah, MD • Muhammad S. Beg, MD • Patrick D. Sutphin, MD, PhD Liquid Biopsy for Cancer: Review and Implications for the Radiologist. Radiology 2020; 294:5-17